Annual report pursuant to Section 13 and 15(d)

License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)

v3.22.0.1
License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 23, 2021
Dec. 30, 2020
Dec. 23, 2020
Aug. 07, 2019
Sep. 05, 2018
Dec. 05, 2013
Nov. 30, 2017
Dec. 19, 2012
Dec. 19, 2012
Nov. 28, 2012
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2015
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Payments for Other Fees             $ 4,500,000            
Cost of Living Adjustments Percentage     62.50%                    
Fair Value Of Shares Issued         $ 285,000                
Operating Lease, Cost                     $ 280,000 $ 209,000  
Operating Lease, Payments                     321,000 309,000  
Non Cash Addition of Right of Use Assets                     $ 538,000    
Operating Lease, Weighted Average Discount Rate, Percent                     8.50%    
Research and Development Expense                     $ 7,800,000 5,131,000  
Cedarssinai Medical Center [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Number Of Common Stock To Be Issued         50,000                
Number Of Common Stock To Be Held By Related Party         7,480,000                
Cedarssinai Medical Center [Member] | SYN Biomics [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Additional Number Of Common Stock To Be Issued         2,420,000                
Operating Lease [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Operating Lease, Cost                       1,300,000  
Licensing Agreements [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Annual payments due under license agreement                 $ 50,000        
Final payment due under license agreement                 25,000        
Payments for Other Fees           $ 150,000              
Stock Issued During Period, Shares, New Issues           9,569              
Patents [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Payments for Other Fees           $ 220,000              
Steven A. Shallcross                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage   62.00%                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   450,000                      
Dr. Sliman [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage 62.50%                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 650,000                        
Annual Base Salary     $ 450,000                    
Prev Abr Llc [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Additional Cash Payment for License Agreement                   $ 235,000      
Unregistered Shares Issued to License Agreement                   17,858      
Additional Consideration Payable                   50% in cash and 50% in our stock      
Options To Be Received Common Stock Shares                         18,724
Phase I Clinical Trials [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Milestone Payment               $ 50,000          
Phase III Clinical Trials [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Milestone Payment               100,000          
NDA Submission In US [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Milestone Payment               250,000          
European Medicines Agency Approval [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Milestone Payment               100,000          
Regulatory Approval In Asian Country [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Milestone Payment               100,000          
Stock Purchase Agreement [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Research and Development Expense                     $ 1,000 $ 225,000  
Clinical Trial Agreement [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Estimated Research Costs       $ 3,200,000                  
First Year [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Research Agreement Fixed Fee               303,287 303,287        
Second Year [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Research Agreement Fixed Fee               316,438 316,438        
Third Year [Member]                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                          
Research Agreement Fixed Fee               $ 328,758 $ 328,758